Revenue: As of FY2025 Q2, the actual value is USD 4.824 K.EPS: As of FY2025 Q2, the actual value is USD 0.EBIT: As of FY2025 Q2, the actual value is USD -132.55 K.<h3>Segment Revenue</h3><ul><li>Revenue: For the three months ended June 30, 2025, revenue was $4,824, compared to $27,594 for the same period in 2024. For the six months ended June 30, 2025, revenue was $4,824, compared to $85,475 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended June 30, 2025, net loss was $287,772, compared to $225,599 for the same period in 2024. For the six months ended June 30, 2025, net loss was $373,260, compared to $478,179 for the same period in 2024.</li><li>Gross Margin: For the three months ended June 30, 2025, gross margin was $4,224, compared to $21,654 for the same period in 2024. For the six months ended June 30, 2025, gross margin was $4,224, compared to $65,945 for the same period in 2024.</li><li>Operating Expenses: For the three months ended June 30, 2025, operating expenses were $136,776, compared to $318,519 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $268,091, compared to $487,025 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: For the six months ended June 30, 2025, cash used in operating activities was $251,368, compared to $265,373 for the same period in 2024.</li><li>Financing Cash Flow: For the six months ended June 30, 2025, the company received $204,000 from the issuance of convertible notes payable. For the six months ended June 30, 2024, the company received $125,000 from the issuance of a convertible note payable and $120,000 from the sale of common stock.</li></ul><h3>Unique Metrics</h3><ul><li>Convertible Notes Payable: As of June 30, 2025, the company had several convertible notes payable with a total principal and interest due of $192,990.</li><li>Derivative Liabilities: As of June 30, 2025, derivative liabilities were valued at $191,306, compared to $152,014 as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue financing its operations through debt and/or equity financing as needed. The company received FDA 510k approval for its DeltaWave product on July 2, 2024, and has begun selling and adding to its inventory of the DeltaWave in the second quarter of 2025.</li><li>Non-Core Business: The company has stopped selling its CPAP machines at the end of 2024 and started selling the DeltaWave in 2025.</li><li>Priority: Management’s plans include obtaining funding from new investors to alleviate working capital deficiency and implementing a plan to generate sales.</li></ul>

REMSleep Holdings, Inc. | 10-Q: FY2025 Q2 Revenue: USD 4.824 K